Table 4.
Types of cancers investigated in the top-cited papers on anti-PD1/PDL1 immunotherapy.
| Cancer type | Number of papers | Total number of citations | Average number of citations (per paper) | Average number of citations per year (per paper) | |
|---|---|---|---|---|---|
| Lung cancer | 30 | 46,422 | 1,547.4 | 336.5 | |
| Melanoma | 20 | 30,881 | 1,544.1 | 266.6 | |
| Urothelial cancer | 10 | 8,484 | 848.4 | 173.4 | |
| Renal cell cancer | 7 | 8,692 | 1,241.7 | 294.5 | |
| Non-specific cancer | 6 | 21,063 | 3,510.5 | 441.1 | |
| Lymphoma | 5 | 4,218 | 843.6 | 132.6 | |
| Gastric cancer | 4 | 2,740 | 685 | 167.1 | |
| Head and neck squamous cell cancer | 4 | 4,241 | 1,060.3 | 260.1 | |
| Hepatocellular cancer | 4 | 4,177 | 1,044.3 | 370.3 | |
| Skin cancer | 3 | 1,938 | 646 | 136.6 | |
| Breast cancer | 3 | 3,077 | 1,025.7 | 300.4 | |
| Colorectal cancer | 2 | 1,873 | 936.5 | 227.7 | |
| Ovarian cancer | 1 | 609 | 609 | 89 | |
| Sarcoma | 1 | 425 | 425 | 88 | |
PD1, programmed cell death 1; PDL1, programmed cell death 1 ligand 1.